These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1944276)

  • 1. Analysis of p53 mutants for transcriptional activity.
    Raycroft L; Schmidt JR; Yoas K; Hao MM; Lozano G
    Mol Cell Biol; 1991 Dec; 11(12):6067-74. PubMed ID: 1944276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
    Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
    Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.
    Unger T; Nau MM; Segal S; Minna JD
    EMBO J; 1992 Apr; 11(4):1383-90. PubMed ID: 1314165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription.
    Liu X; Miller CW; Koeffler PH; Berk AJ
    Mol Cell Biol; 1993 Jun; 13(6):3291-300. PubMed ID: 8497252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Raycroft L; Wu HY; Lozano G
    Science; 1990 Aug; 249(4972):1049-51. PubMed ID: 2144364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian p53 can function as a transcription factor in yeast.
    Schärer E; Iggo R
    Nucleic Acids Res; 1992 Apr; 20(7):1539-45. PubMed ID: 1579447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A significant decrease of the transcriptional activity of p53 mutants deriving from human functional adrenal tumors.
    Lin SR; Yang YC; Jung JH; Tsai JH
    DNA Cell Biol; 1996 Oct; 15(10):793-803. PubMed ID: 8892752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A functionally inactive p53 Li-Fraumeni syndrome mutant.
    Hao M; Finlay CA; Lozano G
    Oncogene; 1993 Feb; 8(2):299-306. PubMed ID: 8426739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
    Kühnel F; Zender L; Wirth T; Schulte B; Trautwein C; Manns M; Kubicka S
    Cancer Gene Ther; 2004 Jan; 11(1):28-40. PubMed ID: 14681724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential transcriptional activation element in the p53 protein.
    O'Rourke RW; Miller CW; Kato GJ; Simon KJ; Chen DL; Dang CV; Koeffler HP
    Oncogene; 1990 Dec; 5(12):1829-32. PubMed ID: 2284102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.
    Deb S; Jackson CT; Subler MA; Martin DW
    J Virol; 1992 Oct; 66(10):6164-70. PubMed ID: 1356162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53.
    Subler MA; Martin DW; Deb S
    J Virol; 1994 Jan; 68(1):103-10. PubMed ID: 8254719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization.
    Iwabuchi K; Li B; Bartel P; Fields S
    Oncogene; 1993 Jun; 8(6):1693-6. PubMed ID: 8502489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SV40 T antigen abrogates p53-mediated transcriptional activity.
    Jiang D; Srinivasan A; Lozano G; Robbins PD
    Oncogene; 1993 Oct; 8(10):2805-12. PubMed ID: 8378089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
    Kichina JV; Rauth S; Das Gupta TK; Gudkov AV
    Oncogene; 2003 Jul; 22(31):4911-7. PubMed ID: 12894234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
    Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
    Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for a distinct inhibitory factor in the regulation of p53 functional activity.
    Wiederschain D; Gu J; Yuan ZM
    J Biol Chem; 2001 Jul; 276(30):27999-8005. PubMed ID: 11382762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic forms of p53 inhibit p53-regulated gene expression.
    Kern SE; Pietenpol JA; Thiagalingam S; Seymour A; Kinzler KW; Vogelstein B
    Science; 1992 May; 256(5058):827-30. PubMed ID: 1589764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
    Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
    Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.